Brenna Cholerton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brenna Cholerton has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
Thomas J. Montine
24 shared publicationsKathryn A. Chung
11 shared publicationsKaren L. Edwards
Department of Epidemiology and Biostatistics, University of California, Irvine, USA
9 shared publicationsShu-Ching Hu
9 shared publications- Cyrus P. Zabetian
Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
8 shared publications Cyrus P. Zabetian
7 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Scientific Reports
Modeling the heterogeneity of cognitive dysfunction in Parkinson’s disease using partially ordered set models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive heterogeneity using Parkinson’s Precision Medicine Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 participants without baseline cognitive dysfunction, 21.2% developed dysfunction by Year 3. After demographic adjustment and Bonferroni correction, cognitive dysfunction at Year 3 was inversely associated with median CPS values for: Attention (across all visits); Executive Functioning and Working Memory (Year 1 onward); and Visuospatial Judgement (baseline only). In multivariable logistic regression, both baseline Attention and Visuospatial Judgement CPS were significant predictors of future impairment without adjustment for baseline disease duration, however, only Visuospatial Judgement CPS remained a significant predictor after the adjustment. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- 16 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessModeling the heterogeneity of cognitive dysfunction in Parkinson’s disease using partially ordered set models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive heterogeneity using Parkinson’s Precision Medicine Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 participants without baseline cognitive dysfunction, 21.2% developed dysfunction by Year 3. After demographic adjustment and Bonferroni correction, cognitive dysfunction at Year 3 was inversely associated with median CPS values for: Attention (across all visits); Executive Functioning and Working Memory (Year 1 onward); and Visuospatial Judgement (baseline only). In multivariable logistic regression, both baseline Attention and Visuospatial Judgement CPS were significant predictors of future impairment without adjustment for baseline disease duration, however, only Visuospatial Judgement CPS remained a significant predictor after the adjustment. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- Open Access
- 7 August 2026
- Published by Elsevier in Academic Pathology
- Vol. 13 (4)
The new normal: Simultaneous temporal increases in workload and physician well-being experienced by Stanford pathology in a transformed work environment
- 7 August 2026
- Published by Elsevier in Academic Pathology
- Vol. 13 (4)
Open AccessThe new normal: Simultaneous temporal increases in workload and physician well-being experienced by Stanford pathology in a transformed work environment
- Open Access
- 29 June 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (6) , e1012170
Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer’s disease and related dementias in a multi-site autopsy cohort
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer’s disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n = 12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson’s disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM/ EED, TMEM106B, GRN, and SNCA/ SNCA-AS1 ) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2/ SLC10A4 ). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics.
- 29 June 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (6) , e1012170
Open AccessGenome wide association study meta-analysis of neuropathologic lesions of Alzheimer’s disease and related dementias in a multi-site autopsy cohort
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer’s disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n = 12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson’s disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM/ EED, TMEM106B, GRN, and SNCA/ SNCA-AS1 ) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2/ SLC10A4 ). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics.
- Open Access
Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer’s disease and related dementias in a multi-site autopsy cohort
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer’s disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n=12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson’s disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM / EED, TMEM106B, GRN, and SNCA / SNCA-AS1 ) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2 / SLC10A4 ). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics. Author Summary: Clinically diagnosed Alzheimer’s disease (AD) dementia is commonly associated with its hallmark pathologic changes plus neuropathologic features of prevalent co-morbid diseases such as cerebrovascular disease, Lewy body disease, and more recently discovered abnormalities in protein called TDP-43 (collectively, AD related dementias; ADRD). As a result, previous studies that associated clinical diagnosis of AD with specific genes may not tell us the whole story. For this study, we gathered autopsy and genetic data to identify relationships between genes and dementia-associated brain changes. We found some relationships between these diseases and genes that had been previously identified as contributing to clinical dementia, as well as some new relationships that had been previously unknown. We also found that some genes that had previously been identified in relation to AD were associated with different dementia-associated brain lesions. Finally, we found that the various brain lesions differ in the proportion that can be attributed to genetic vs. environmental differences. These results support that the pathway to a diagnosis of dementia can be caused by multiple factors and are an important step in beginning to identify individually based dementia treatments.
Open AccessGenome wide association study meta-analysis of neuropathologic lesions of Alzheimer’s disease and related dementias in a multi-site autopsy cohort
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer’s disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n=12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson’s disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM / EED, TMEM106B, GRN, and SNCA / SNCA-AS1 ) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2 / SLC10A4 ). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics. Author Summary: Clinically diagnosed Alzheimer’s disease (AD) dementia is commonly associated with its hallmark pathologic changes plus neuropathologic features of prevalent co-morbid diseases such as cerebrovascular disease, Lewy body disease, and more recently discovered abnormalities in protein called TDP-43 (collectively, AD related dementias; ADRD). As a result, previous studies that associated clinical diagnosis of AD with specific genes may not tell us the whole story. For this study, we gathered autopsy and genetic data to identify relationships between genes and dementia-associated brain changes. We found some relationships between these diseases and genes that had been previously identified as contributing to clinical dementia, as well as some new relationships that had been previously unknown. We also found that some genes that had previously been identified in relation to AD were associated with different dementia-associated brain lesions. Finally, we found that the various brain lesions differ in the proportion that can be attributed to genetic vs. environmental differences. These results support that the pathway to a diagnosis of dementia can be caused by multiple factors and are an important step in beginning to identify individually based dementia treatments.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e106793
Neuropsychiatric symptom subtypes associated with Alzheimer's disease and related dementia neuropathologic changes in the National Alzheimer's Coordinating Center neuropathology cohort
Background: Neuropsychiatric symptoms (NPS) are highly prevalent in Alzheimer's disease (AD) and related dementias and are responsible for a substantial proportion of disease‐associated burden. Differences in timing and type of NPSmay result from distinct underlying diseases and may be important in predicting outcomes. As such, we examined whether specific NPS clusters (early psychosis/agitation [EPA], late psychosis/agitation [LPA], or affective symptoms [AS]) had distinct associations with common dementia‐associated neuropathologic lesions and/or total neuropathologic burden. Additionally, we assessed whether AD neuropathologic change (ADNC) in the presence or absence of non‐ADNC lesions had differential associations with NPS subtypes. Method: Data were obtained from the National Alzheimer's Coordinating Center (NACC) Uniform and Neuropathology datasets. NPS subtypes were retroactively assigned using the Neuropsychiatric Inventory Questionnaire. Neuropathologic lesions were described in harmonized form across NACC sites. Adjusted logistic regression analyses estimated associations between NPS subtypes and individual neuropathologic changes, total neuropathologic burden, and ADNC in the presence/absence of non‐ADNCs. Result: Among participants diagnosed with dementia ( n = 2352), EPA was associated with Lewy body (OR=2.4, p p p p p p p p p p p <0.0001), while both LPA and EPA were all associated with ADNC+WMD (ORs=2.9, 3.6, p values<0.0001). All subtypes were associated with increased total neuropathologic burden. Conclusion: We found that timing of symptom onset and specific symptom cluster had distinct patterns of association with neuropathologic lesions, and that these may differ according to the presence and severity of concurrent ADNC. Additionally, we report that NPS increased significantly with the number of neuropathologic changes present, providing support for reducing total neuropathologic burden, perhaps through lifestyle modification and disease‐modifying treatments, as a method for harm‐reduction in dementia.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e106793
Open AccessNeuropsychiatric symptom subtypes associated with Alzheimer's disease and related dementia neuropathologic changes in the National Alzheimer's Coordinating Center neuropathology cohort
Background: Neuropsychiatric symptoms (NPS) are highly prevalent in Alzheimer's disease (AD) and related dementias and are responsible for a substantial proportion of disease‐associated burden. Differences in timing and type of NPSmay result from distinct underlying diseases and may be important in predicting outcomes. As such, we examined whether specific NPS clusters (early psychosis/agitation [EPA], late psychosis/agitation [LPA], or affective symptoms [AS]) had distinct associations with common dementia‐associated neuropathologic lesions and/or total neuropathologic burden. Additionally, we assessed whether AD neuropathologic change (ADNC) in the presence or absence of non‐ADNC lesions had differential associations with NPS subtypes. Method: Data were obtained from the National Alzheimer's Coordinating Center (NACC) Uniform and Neuropathology datasets. NPS subtypes were retroactively assigned using the Neuropsychiatric Inventory Questionnaire. Neuropathologic lesions were described in harmonized form across NACC sites. Adjusted logistic regression analyses estimated associations between NPS subtypes and individual neuropathologic changes, total neuropathologic burden, and ADNC in the presence/absence of non‐ADNCs. Result: Among participants diagnosed with dementia ( n = 2352), EPA was associated with Lewy body (OR=2.4, p p p p p p p p p p p <0.0001), while both LPA and EPA were all associated with ADNC+WMD (ORs=2.9, 3.6, p values<0.0001). All subtypes were associated with increased total neuropathologic burden. Conclusion: We found that timing of symptom onset and specific symptom cluster had distinct patterns of association with neuropathologic lesions, and that these may differ according to the presence and severity of concurrent ADNC. Additionally, we report that NPS increased significantly with the number of neuropathologic changes present, providing support for reducing total neuropathologic burden, perhaps through lifestyle modification and disease‐modifying treatments, as a method for harm‐reduction in dementia.
- 27 September 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 108066
Epigenomic profile of GBA1 in Parkinson's disease
- 27 September 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 108066
Epigenomic profile of GBA1 in Parkinson's disease
- Open Access
- 24 September 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70622
Neuropsychiatric symptom subtypes and dementia‐associated neuropathologic change
INTRODUCTION: Neuropsychiatric symptoms (NPS) are prevalent in clinically diagnosed Alzheimer's disease (AD), yet their etiology remains unclear. We assessed associations between NPS and neuropathologic features in dementia patients. METHODS: Logistic regression analyses estimated associations between neuropathologic lesions and retroactively assigned NPS phenotypes (early and late psychosis [EPS, LPS], early and late affective symptoms [EAS, LAS]). RESULTS: EPS was associated with Lewy body (odds ratio [OR] = 2.4, p < 0.0001) and white matter (OR = 1.7, p < 0.0001) pathology. LPS was associated with moderate/severe neurofibrillary tangles (OR = 2.8, p < 0.0001), moderate/frequent neuritic plaques (OR = 2.3, p < 0.0001), Lewy bodies (OR = 1.9, p < 0.0001), and cerebral amyloid angiopathy (OR = 1.6, p < 0.0001). EAS was associated with white matter injury (OR = 3.4, p < 0.0001); EAS and LAS were associated with moderate/severe neurofibrillary tangles (ORs = 1.7, 1.9, p < 0.005). Risk for EPS, LPS, and EAS increased with total neuropathologic burden. DISCUSSION: NPS subtypes are differentially associated with AD/non‐AD neuropathologic features, suggesting that efficiency of interventional targets may depend upon timing and type of NPS. Highlights: Timing/nature of neuropsychiatric symptoms (NPS) had distinct associations with brain autopsy findings in the National Alzheimer's Coordinating Center. Increased odds for psychosis symptoms was associated with both Alzheimer's disease neuropathologic change (ADNC) and Lewy body dementia (LBD). Late psychosis symptoms (PS) was most strongly associated with ADNC, early PS most strongly with LBD. Early PS and affective symptoms were both associated with white matter disease.
- 24 September 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70622
Open AccessNeuropsychiatric symptom subtypes and dementia‐associated neuropathologic change
INTRODUCTION: Neuropsychiatric symptoms (NPS) are prevalent in clinically diagnosed Alzheimer's disease (AD), yet their etiology remains unclear. We assessed associations between NPS and neuropathologic features in dementia patients. METHODS: Logistic regression analyses estimated associations between neuropathologic lesions and retroactively assigned NPS phenotypes (early and late psychosis [EPS, LPS], early and late affective symptoms [EAS, LAS]). RESULTS: EPS was associated with Lewy body (odds ratio [OR] = 2.4, p < 0.0001) and white matter (OR = 1.7, p < 0.0001) pathology. LPS was associated with moderate/severe neurofibrillary tangles (OR = 2.8, p < 0.0001), moderate/frequent neuritic plaques (OR = 2.3, p < 0.0001), Lewy bodies (OR = 1.9, p < 0.0001), and cerebral amyloid angiopathy (OR = 1.6, p < 0.0001). EAS was associated with white matter injury (OR = 3.4, p < 0.0001); EAS and LAS were associated with moderate/severe neurofibrillary tangles (ORs = 1.7, 1.9, p < 0.005). Risk for EPS, LPS, and EAS increased with total neuropathologic burden. DISCUSSION: NPS subtypes are differentially associated with AD/non‐AD neuropathologic features, suggesting that efficiency of interventional targets may depend upon timing and type of NPS. Highlights: Timing/nature of neuropsychiatric symptoms (NPS) had distinct associations with brain autopsy findings in the National Alzheimer's Coordinating Center. Increased odds for psychosis symptoms was associated with both Alzheimer's disease neuropathologic change (ADNC) and Lewy body dementia (LBD). Late psychosis symptoms (PS) was most strongly associated with ADNC, early PS most strongly with LBD. Early PS and affective symptoms were both associated with white matter disease.
- Open Access
Modeling the Heterogeneity and Trajectories of Cognitive Dysfunction in Parkinson’s Disease Using Partially Ordered Set Models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive trajectories using Parkinson’s Progression Markers Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 patients without baseline cognitive dysfunction, 21.7% developed dysfunction by Year 3. These individuals exhibited significantly lower median CPS across all domains during follow up visits in Years 1-3. Notably, baseline Attention and Visuospatial CPS were significant predictors of future impairment, with an area under the curve (AUC) of 0.782; a specificity of 91.3%, and a sensitivity or 35.7%. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
Open AccessModeling the Heterogeneity and Trajectories of Cognitive Dysfunction in Parkinson’s Disease Using Partially Ordered Set Models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive trajectories using Parkinson’s Progression Markers Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 patients without baseline cognitive dysfunction, 21.7% developed dysfunction by Year 3. These individuals exhibited significantly lower median CPS across all domains during follow up visits in Years 1-3. Notably, baseline Attention and Visuospatial CPS were significant predictors of future impairment, with an area under the curve (AUC) of 0.782; a specificity of 91.3%, and a sensitivity or 35.7%. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- Open Access
- 18 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (9) , 1791-1804
Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations
Background: Cognitive impairment in Parkinson's disease (PD) is a well‐established non‐motor complication that significantly affects the quality of life and well‐being of both patients and care partners. To optimally detect mild cognitive impairment or dementia, extensive neuropsychological assessment is essential. A wide range of cognitive tests and clinical outcome assessments have been used in clinical settings, often without regard to their clinimetric quality.Methods: We performed a literature review of tests assessing attention/working memory and executive domains in PD (tests on other domains are included in an accompanying review). The selected tests were evaluated for their clinimetric properties and categorized by a panel of experts as “recommended,” “recommended with caveats,” “suggested,” or “listed” according to the International Parkinson and Movement Disorder Society Clinical Outcome Assessment Scientific Evaluation Committee guidelines.Results: A total of 30 tests were reviewed. Eight tests were “recommended,” including four tests assessing attention/working memory abilities (WAIS‐IV Digit Span, Coding and Symbol Search subtests, and Trail Making Test) and four tests assessing executive abilities (WAIS‐IV Similarities, Wisconsin Card Sorting Test, Fluency Tests, and Stroop Color‐Word Test). These tests demonstrated good to excellent levels of reliability and validity, have normative datasets, and are sensitive to change. Eight other tests were “recommended with caveats”, eleven were “suggested,” and three were “listed.”Conclusions: The recommended tests for attention/working memory and executive functioning in PD can guide PD cognitive assessment. Other tests were identified as potentially useful; however, caution is advised due to their clinimetric limitations. Further validation studies are required for these tests. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 18 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (9) , 1791-1804
Open AccessAttention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations
Background: Cognitive impairment in Parkinson's disease (PD) is a well‐established non‐motor complication that significantly affects the quality of life and well‐being of both patients and care partners. To optimally detect mild cognitive impairment or dementia, extensive neuropsychological assessment is essential. A wide range of cognitive tests and clinical outcome assessments have been used in clinical settings, often without regard to their clinimetric quality.Methods: We performed a literature review of tests assessing attention/working memory and executive domains in PD (tests on other domains are included in an accompanying review). The selected tests were evaluated for their clinimetric properties and categorized by a panel of experts as “recommended,” “recommended with caveats,” “suggested,” or “listed” according to the International Parkinson and Movement Disorder Society Clinical Outcome Assessment Scientific Evaluation Committee guidelines.Results: A total of 30 tests were reviewed. Eight tests were “recommended,” including four tests assessing attention/working memory abilities (WAIS‐IV Digit Span, Coding and Symbol Search subtests, and Trail Making Test) and four tests assessing executive abilities (WAIS‐IV Similarities, Wisconsin Card Sorting Test, Fluency Tests, and Stroop Color‐Word Test). These tests demonstrated good to excellent levels of reliability and validity, have normative datasets, and are sensitive to change. Eight other tests were “recommended with caveats”, eleven were “suggested,” and three were “listed.”Conclusions: The recommended tests for attention/working memory and executive functioning in PD can guide PD cognitive assessment. Other tests were identified as potentially useful; however, caution is advised due to their clinimetric limitations. Further validation studies are required for these tests. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213648
The Parkinson's Disease Composite of Executive Functioning
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (11) , e213648
The Parkinson's Disease Composite of Executive Functioning